SCHEMBL7084050

SCHEMBL7084050

O=C(Nc1ccc(Cl)c(-c2cccnc2)c1)Oc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
PORCN Q9H237 2/20 0.53
ABL1 P00519 1/20 0.53
KDR P35968 1/20 0.52
ROCK2 O75116 1/20 0.51
MTOR P42345 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 3/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
KDM4E B2RXH2 1/20 0.47
CNR1 P21554 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7079643 0.84 POLB (0.60) POLBPORCNABL1KDRROCK2
SCHEMBL7078069 0.83 PORCN (0.53) POLBPORCNROCK2ALDH1A1MAPT
SCHEMBL1568942 0.83 PORCN (0.60) PORCNROCK2ALDH1A1MAPTKMT2A
SCHEMBL7078347 0.80 PORCN (0.60) PORCNKDRROCK2ALDH1A1MAPT
SCHEMBL6079377 0.80 MAPK14 (0.58) POLBPORCNROCK2ALDH1A1MAPT
SCHEMBL7945550 0.79 PORCN (0.49) PORCNROCK2ALDH1A1MAPTMEN1
SCHEMBL7078078 0.79 PORCN (0.56) PORCNROCK2ALDH1A1MAPTMEN1
SCHEMBL241619 0.78 NPC1 (0.63) ALDH1A1MAPTLMNAHTTKMT2A
SCHEMBL30063430 0.78 POLB (0.72) POLBALDH1A1MAPTMEN1LMNA
SCHEMBL11175842 0.78 POLB (0.72) POLBALDH1A1MAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1151147-C Indole derivatives as 5 -HT receptor antagonist ʷ��˿�������ȳ�ķ���޹�˾ 2004-05-26 CN disclosed
US-6638953-B2 Central nervous system disorders; anxiety SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-28 US disclosed
US-20030105139-A1 Indole derivatives as 5-HT receptor antagonist SMITHKLINE BEECHAM P.L.C. 2003-06-05 US disclosed
US-6235758-B1 CENTRAL NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-22 US disclosed
EP-0808312-B1 INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST SMITHKLINE BEECHAM PLC (GB) 2000-11-02 EP disclosed
US-5990133-A TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY OR DEPRESSION SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-23 US disclosed
CN-1179156-A Indole derivatives as 5-HT receptor antagonists SMITHKINE BEECHAM PLC (GB) 1998-04-15 CN disclosed
EP-0808312-A1 INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST SMITHKLINE BEECHAM PLC (GB) 1997-11-26 EP disclosed
WO-1996023783-A1 INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST SMITHKLINE BEECHAM PLC (GB) 1996-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105139-A1 Indole derivatives as 5-HT receptor antagonist HTR5A, HTR2C, HTR1A POLB 4627/4885PORCN 2670/4885ABL1 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.